Metabolism of a new neuroprotector GZK-111 (N-phenylacetylglycyl-L-proline ethyl ester) in rat blood plasma was studied by HPLC-mass spectrometry. Four biotransformation products were identified. It is concluded that the main ways of GZK-111 biotransformation are hydrolysis of the ester bond by esterases followed by degradation of the resulting metabolite, as well as reactions leading to the formation of phenylacetic acid and cycloprolylglycine that exhibits neuropsychotropic activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boiko SS, Korotkov SA, Zherdev VP, Gudasheva TA, Ostrovskaya RU. Pharmacokinetics of a new potential dipeptide nootropic drug GVS-111 and its metabolites in the rat brain. Khim.-Farm. Zh. 2001;35(9):11-13. Russian.
Zherdev VP, Boyko SS, Shevchenko RV, Bochkov PO, Gribakina OV, Raskin SYu. The role of studies of interspecies differences pharmacokinetics in the creation of new peptide drugs. Eksp. Klin. Farmakol. 2004;67(1):40-43. doi: https://doi.org/10.30906/0869-2092-2004-67-1-40-43.Russian.
Gudasheva TA, Kolyasnikova KN, Kuznetsova EA, Litvinova SA, Zolotov NN, Voronina TA, Ostrovskaya RU, Seredenin SB. N-phenylacetyl-glycyl-L-proline ethyl ester converts into cyclo-L-prolyl-glycine showing a similar spectrum of neuropsychotropic activity. Khim.-Farm. Zh. 2016;50(11):3-8. Russian.
Seredenin SB, Gudasheva TA, Kolyasnikova KN, Kuznetsova EA, Voronina TA, Yarkova MA, Antipova TA, Litvinova SA, Zolotov NN. Patent RU No. 2646604. Novel glyprolins with nootropic, anti-hypoxic, neuroprotective and anssiylitis activity. Bull. No. 7. Published March 6, 2018.
Diao L, Meibohm B. Pharmacokinetics and pharmacokineticpharmacodynamic correlations of therapeutic peptides. Clin. Pharmacokinet. 2013;52(10):855-868. doi: https://doi.org/10.1007/s40262-013-0079-0
Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J. Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients. Ann. Clin. Transl. Neurol. 2019;6(4):669-677. doi: https://doi.org/10.1002/acn3.743
Gudasheva TA, Boyko SS, Akparov VKh, Ostrovskaya RU, Skoldinov SP, Rozantsev GG, Voronina TA, Zherdev VP, Seredenin SB. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Lett. 1996;391(1-2):149-152. doi: https://doi.org/10.1016/0014-5793(96)00722-3
Koliasnikova KN, Povarnina PY, Tallerova AV, Firsova YN, Nikolaev SV, Antipova TA, Nadorova AV, Kolik LG, Gudasheva TA, Seredenin SB. Glyproline Pro-Ampakine with neuroprotective activity. Neuroprotection. New Approaches and Prospects. Otero-Losada M, ed. IntechOpen, 2020. doi: https://doi.org/10.5772/intechopen.91192
Malavolta L, Cabral FR. Peptides: important tools for the treatment of central nervous system disorders. Neuropeptides. 2011;45(5):309-316. doi: https://doi.org/10.1016/j.npep.2011.03.001
Manabe S, Machida H, Aihara Y, Yasunaga M, Ito Y, Matsumura Y. Development of a diketopiperazine-forming dipeptidyl Gly-Pro spacer for preparation of an antibody-drug conjugate. Med. Chem. Comm. 2013;4(5):792-796. doi: https://doi.org/10.1039/C3MD00075C
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 172, No. 11, pp. 618-621, November, 2021
Rights and permissions
About this article
Cite this article
Kolyvanov, G.B., Bochkov, P.O., Litvin, A.A. et al. Metabolism of a New Dipeptide Neuroprotector in Rats. Bull Exp Biol Med 172, 579–582 (2022). https://doi.org/10.1007/s10517-022-05440-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-022-05440-3